What is the difference between Entrectinib and Lorlatinib? Which one is better?

Entrectinib and lorlatinib (Lorlatinib) are targeted therapy drugs used to treat cancers such as lung cancer. They have some differences, including indications, mechanism of action, efficacy, etc. Which one is better depends on the patient's specific situation and tumor characteristics.

Entrectinib (Entrectinib):

1.Indications: Entrectinib is suitable for patients carrying ROS1, NTRK and ALK gene fusions. It can be used to treat lung cancer and other solid tumors that are positive for these gene fusions.

2.Mechanism of action: Entrectinib is a multi-target inhibitor that interferes with the signaling pathways in tumor cells by inhibiting the activity of kinases such as ROS1, NTRK and ALK, thereby inhibiting tumor growth and spread.

3.Efficacy: Entrectinib has shown significant efficacy in clinical trials, especially in tumors carrying specific gene fusions. Clinical trial data indicate that entrectinib can induce tumor shrinkage or stabilization in patients with these gene fusion-positive tumors.

lorlatinib (Lorlatinib):

1.Indications: Lorlatinib is mainly suitable for advanced non-small cell lung cancer with ALK and ROS1 gene fusion (NSCLC), these gene fusions may lead to resistance to traditional ALK inhibitors and ROS1 inhibitors.

2.Mechanism of action: Lorlatinib is a multi-target inhibitor that can act on multiple fusion proteins at the same time, includingALK, ROS1and other kinases. It inhibits tumor growth by inhibiting the activity of these fusion proteins and interfering with signaling within tumor cells.

3.Efficacy: Lorlatinib has also shown good efficacy in clinical trials, especially in NSCLC patients with ALK and ROS1 gene fusions. It has also been shown to have therapeutic benefits in some drug-resistant patients.

哪个药物更好取决于患者的具体情况。 If a patient's tumor carries a ROS1, NTRK, or ALK gene fusion, entrectinib may be a more suitable option. And if the tumor carries ALK and ROS1 gene fusion and has developed drug resistance, then lorlatinib may be more suitable. However, the final treatment decision should be made under the guidance of a doctor, who will develop the most appropriate treatment plan based on the patient's genotype, tumor characteristics, health status and other comprehensive factors.

Regardless of which drug is chosen, regular medical monitoring and follow-up are very important to ensure that patients get the best results from their treatment.

Entrectinib has been launched in China, but due to its short time on the market, it has not yet been included in the medical insurance catalog. Since it has just been launched, it is difficult to purchase domestically and the price is very high. For specific prices, please consult the hospital pharmacy at that time. There are original drugs and generic drugs abroad. The original drugs abroad are mainly European versions of original drugs. The price is about 45,000 yuan. The price is relatively high and may be unaffordable for ordinary families. Generic drugs are mainly Lao generic drugs, with prices ranging from 4,000 to 8,000yuan, which are much cheaper than original drugs, and the ingredients of original drugs and generic drugs are basically the same.

On April 29, 2022, lorlatinib was approved by the National Medical Products Administration (NMPA) n>Approved for marketing, and will be included in medical insurance in 2023. Patients can purchase it domestically. The current price of lorlatinib in China is about 2000It’s about RMB 1,000. Please consult your local pharmacy for specific prices and medical insurance reimbursement. In addition to domestic original drugs, there are also foreign original drugs and generic drugs. Foreign original drugs are mainly Turkish version of original drugs, and the price is about 13,000~14,000 yuan; secondly, there are cheaper foreign generic drugs, such as Laos generic drugs, with prices ranging from 1,200 to 3,800 yuan. The ingredients of the drugs are the same as the original drugs.